Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized trial
Atopic dermatitis, commonly known as eczema, can cause dry, itchy, and painful skin. Dupilumab (Dupixent) is an effective injection that helps many people get their eczema under control. However, doctors want to know if people who are doing very well need to keep taking the full, regular dose. This clinical trial is testing a 'step-down' approach over one year. Participants whose eczema is in remission will try reducing how much dupilumab they use or how often they take it. Researchers will track skin symptoms, itchiness, and quality of life at regular clinic check-ups. Topical creams are also available if eczema flares up. The goal is to see if a lower treatment schedule works just as well as standard dosing. If successful, this could mean fewer injections for patients and better value for the NHS.
At a glance
What is this study about?
Atopic eczema is a long-term condition that causes itchy, sore, and inflamed skin. For people with moderate to severe eczema, an injectable medicine called dupilumab (brand name Dupixent) can be life-changing. It works by targeting specific signals in the immune system to calm inflammation and clear the skin.
Once a person's skin is clear and stays that way (a state called remission), doctors wonder if the regular full dose is still needed. Taking medicine only when necessary can reduce the burden of regular injections, cut the chance of side effects, and save money for healthcare services like the NHS. This approach of gently reducing medicine is known as a 'step-down' strategy.
In this study, researchers are comparing standard dupilumab dosing against a reduced schedule over the course of one year. The team wants to prove that stepping down does not make skin control worse. Participants will still have access to soothing and medicated creams if they experience any breakthrough patches of eczema.
By taking part, patients help doctors understand how to fine-tune long-term eczema treatment. If the study shows that lower doses work just as well, it could change standard guidelines and help many people manage their eczema with fewer injections.
Key takeaways
- Tests whether people with clear skin can take less dupilumab without their eczema returning.
- Lasts for 12 months with clinic check-ups at 4, 8, and 12 months.
- Open to adults aged 18 and over whose eczema is currently well controlled on dupilumab.
- Medicated creams are provided if you experience any sudden skin flares.
- Taking part is voluntary, and you can stop at any point while keeping your standard care.
Who may be eligible?
This trial is open to adults aged 18 and older who have atopic eczema. To take part, your eczema must currently be well controlled or in remission thanks to treatment with dupilumab injections.
You should be comfortable giving yourself injections (or having a carer help you) using pre-filled pens or syringes, and willing to attend routine hospital check-ups over a 12-month period. You may also need to use skin creams if you have any sudden flare-ups.
You might not be able to take part if you have certain other medical conditions, severe infections, or if your eczema is currently very active and uncontrolled. Your dermatology doctor will review your full medical history to confirm whether this trial is safe and suitable for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with atopic dermatitis (eczema).
- I am currently using dupilumab (Dupixent) injections.
- My eczema is currently well controlled or mostly clear.
- I am willing to attend clinic check-ups over a 12-month period.
What does participation involve?
Taking part in this study lasts for one year. You will be assigned to a treatment plan that involves taking dupilumab, which might be at standard intervals or spaced out further as part of the step-down plan. You will receive the medicine as an injection using a pre-filled pen or syringe. You will also be given skin creams to use if your eczema begins to flare.
You will visit the clinic for assessments at the start of the study, and then at roughly 4 months, 8 months, and 12 months. During these visits, doctors will check your skin, measure any redness or dryness, and ask about your itching levels. You will also complete short questionnaires to see how eczema affects your daily life and sleep. Between visits, you may be asked to keep a simple weekly record of your symptoms.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is a 'step-down' strategy?
It means slowly reducing the amount or frequency of a medication once your condition is stable, to see if a smaller amount works just as well.
What happens if my eczema gets worse during the study?
Your study team will give you medicated topical creams to treat flares quickly. If needed, your doctor can adjust your treatment to get your skin back under control.
How is the medicine given?
Dupilumab is given as a simple injection under the skin using an easy-to-use pre-filled pen or syringe.
Will taking part cost me anything?
No, the study medication and extra trial assessments are provided at no cost to you. Some trials may also help with travel expenses for clinic visits.
Can I leave the trial if I change my mind?
Yes, you can leave the study at any time without giving a reason. Your regular doctor will then switch you back to your usual eczema care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.